Pre-radiation chemotherapy for high-grade glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial investigates whether administering temozolomide prior to radiotherapy is feasible and beneficial for adults with high-grade gliomas. The study uses a pre-radiation approach with an FDA-approved chemotherapy to potentially improve treatment response and simplify post-treatment MRI interpretation. Eligible participants have residual measurable post-operative tumor and adequate organ function, with no urgent need for immediate radiation. If successful, the method may serve as a screening approach for future drug testing in this setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologic diagnosis of high-grade glioma
2. Residual measurable post-operative contrast enhancing tumor
3. Lack of urgency in requiring immediate radiation or chemotherapy (mass effect, mid-line shift, herniation, etc.)
4. Ability to provide informed consent
5. Willingness to comply with all study procedures and availability for the duration of the study
6. Male or female, aged 18-80.
7. Karnofsky Performance Status ³70%.
8. Patients must have the following organ and marrow functions:

   Absolute neutrophil count ≥1,500/µL Platelets ≥100,000/µL Hemoglobin ≥ 9 g/dL Total bilirubin £ 1.5 × institutional upper limit of normal (ULN), (except for patients with known Gilbert's syndrome who must have normal direct bilirubin) AST (SGOT)/ALT (SGPT) £ 2.5 × ULN Creatinine £ 1.5 × ULN OR Creatinine clearance ≥ 60 mL/min/1.73m2 APTT/PTT ≤ 1.5 × ULN Sodium ≥ the institutional lower limit of normal
9. Ability to take oral medication and be willing to adhere to the pre-radiation temozolomide regimen
10. For females of reproductive potential: use of highly effective contraception for at least 1 week prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of pr-radiation temozolomide administration
11. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
12. Patients must have measurable disease as defined by RANO criteria.

Exclusion Criteria:

1. Patients receiving any other investigational agents are ineligible.
2. Patients who had Gliadel wafer or other local therapy placed in the tumor cavity during the tumor resection.
3. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to TMZ are ineligible.
4. Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible.
5. Pregnant women are excluded from this study because TMZ has potential for teratogenic or abortifacients effects. Breastfeeding should be discontinued if the mother is treated with TMZ.

Where it's running

• Cooper University HealthCare
  Camden, New Jersey, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FT536 injection for recurrent WHO Grade 4 astrocytoma

  This will try a single intratumoral dose of FT536, an off-the-shelf engineered NK‑cell therapy, in adults undergoing repeat surgery for recurrent Grade 4 astrocytoma.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07560865

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• FearLess for adults with malignant brain tumors and their caregivers

  This project will test whether the FearLess psychological program can reduce fear of cancer recurrence in adults with primary malignant brain tumors and their nonprofessional caregivers.

  Recruiting Virginia Commonwealth University · Richmond, Virginia · NCT06989086

• Local targeted therapy for recurrent glioblastoma using alpha emitter.

  This study is testing a new targeted treatment for adults with recurrent high-grade gliomas to see if it can help them after standard therapies have failed.

  Recruiting at 2 sites Medical University of Warsaw · Warsaw, Poland and 1 other locations · NCT06975332

• Understanding brain blood flow and metabolism in patients with brain lesions

  This study is trying to understand how blood flow and metabolism in the brain are affected in patients with brain tumors like glioblastoma, glioma, and astrocytoma.

  Recruiting Erasme University Hospital · Brussels · NCT06797661

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.